| HOME >> BIOLOGY >> TECHNOLOGY |
HANGZHOU, China, Nov. 20 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) today announced its new plan of operation to take closer control and to better improve its current operation results. The company also plans to move away from the increasingly competitive and low margin vaccine business, and to enter new specialty pharmaceutical products.
"We plan to take more control on the available cash in out subsidiaries and move into higher market potential and higher margin specialty pharmaceutical products," says Peter Wang, CEO and Chairman of Board. "And we are negotiating with a few global vaccine manufacturers now for carrying their higher margin products, in order to avoid direct competitions with other manufacturers."
Recent changes in vaccine sectors have resulted in more vaccine manufacturers entering into low margin vaccine business such as flu vaccine, thus creating severe competition among, and squeezed profit margin of, vaccine distributors such as China Biopharma. Besides moving away from the low margin vaccine business, the company also starts to enter specialty pharmaceutical products such as the recently released anti-viral products.
China Biopharma has most of its operation in China. Working to take direct control on subsidiaries' operation and financial management, the company plans to increase its shareholding in China Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture. With internally available resources, there would be no need to raise additional capital to complete the transactions. This is expected to improve current performance and increase operation stability.
"This new direction is expected to preserve available cash position and
give us more operation flexibility," says Chunhui Shu, the new interim
Chief Financial Officer. "In view of improvement and progress on our
current operation results, we have made this plan to take more e
'/>"/>
| SOURCE China Biopharma, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |